MS-20

DRUG4 trials

Sponsors

Microbio Co Ltd, National Taiwan University Hospital

Conditions

CachexiaChemotherapy EffectHepatocellular CarcinomaMicrobiotaNSCLC Stage IIIB~IVPancreatic Cancer

Phase 2

Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)

Microbio Co LtdHepatocellular Carcinoma

Start: 2008-03-31End: 2010-12-31Target: 60Updated: 2010-02-26

Unknown Phase

MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients

National Taiwan University HospitalCachexia, Chemotherapy Effect, Pancreatic Cancer

Start: 2021-08-10End: 2023-06-30Target: 40Updated: 2023-01-19

The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals

CompletedNCT04674839

Microbio Co LtdMicrobiota

Start: 2019-10-18End: 2020-11-20Updated: 2020-12-23

A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

CompletedNCT04909034

Microbio Co LtdNSCLC Stage IIIB~IV

Start: 2021-08-20End: 2024-11-30Updated: 2024-12-18